The drugs currently available to combat leishmaniasis, a disease that affects populations in socioeconomically disadvantaged regions and that can lead to death, are ineffective, elicit severe and persistent side effects, and require long-term treatment. there is a demand for drugs that eliminate the parasite quickly and effectively without compromising the patient’s health.
This newly developed product includes new derivatives that, in laboratory tests, showed higher indices of selectivity for leishmaniasis agents than the drugs currently in use, as well as low toxicity and safer and more effective treatments. in addition to leishmaniasis, the product has a potential for therapeutic use in combating other diseases, such as viral, cardiovascular, inflammatory, metabolic, bacterial, and fungal diseases, cancer and trypanosomiasis.
Agência Unesp de Inovação
Tel: +55 11 5627.0696
[PodInovar] Parceria com AUIN é fundamental no desenvolvimento de eventos de tecnologia e empreendedorismo, destaca coordenadora do IBIT
Acesse aqui os registros de patentes da UNESP
Portal do ex-aluno